Anders Junker
Overview
Explore the profile of Anders Junker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
793
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hansen K, Maehara A, Troan J, Noori M, Hougaard M, Ellert J, et al.
Cardiovasc Revasc Med
. 2025 Mar;
PMID: 40074646
Background: Lumen reduction after bioresorbable scaffold implantation has been reported. This study aimed to assess the influence of pre-dilatation with a scoring balloon versus a standard non-compliant balloon prior to...
2.
Hansen K, Troan J, Maehara A, Noori M, Hougaard M, Ellert-Gregersen J, et al.
Circ Cardiovasc Interv
. 2025 Jan;
18(1):e014665.
PMID: 39836741
Background: Bioresorbable scaffolds (BRS) were developed to overcome limitations related to late stent failures of drug-eluting stents, but lumen reductions over time after implantation of BRS have been reported. This...
3.
Klein A, Beske R, Hassager C, Jensen L, Eiskjaer H, Mangner N, et al.
J Am Coll Cardiol
. 2024 Nov;
85(6):595-603.
PMID: 39551167
Background: Whether age impacts the recently demonstrated survival benefit of microaxial flow pump (mAFP) treatment in patients with ST-segment elevation myocardial infarction (STEMI) and cardiogenic shock (CS) is unknown. Objectives:...
4.
Zweck E, Hassager C, Beske R, Jensen L, Eiskjaer H, Mangner N, et al.
Circulation
. 2024 Oct;
150(25):1990-2003.
PMID: 39462276
Background: In DanGer Shock (the Danish-German Cardiogenic Shock trial), use of a microaxial flow pump (mAFP) in patients with ST-segment-elevation myocardial infarction-related cardiogenic shock led to lower all-cause mortality but...
5.
Udesen N, Beske R, Hassager C, Jensen L, Eiskjaer H, Mangner N, et al.
JAMA Cardiol
. 2024 Oct;
10(1):9-16.
PMID: 39462240
Importance: Mechanical circulatory support with a microaxial flow pump (MAFP) has been shown to improve survival in ST-elevation myocardial infarction-induced cardiogenic shock (STEMI-CS). Understanding the impact on hemodynamic stability over...
6.
Jakobsen L, Christiansen E, Freeman P, Kahlert J, Veien K, Maeng M, et al.
Am J Cardiol
. 2024 Oct;
235():1-8.
PMID: 39461401
In-stent restenosis (ISR) still occurs after percutaneous coronary intervention (PCI). Few studies have compared the outcomes of PCI for de novo stenosis with those of PCI for ISR, and the...
7.
Thangavel S, Madsen K, Ronnow Sand N, Veien K, Deibjerg L, Husain M, et al.
Int J Cardiovasc Imaging
. 2024 Sep;
40(10):2213-2220.
PMID: 39259436
Coronary CT angiography (CTA) derived fractional flow reserve (FFR) is recommended for physiological assessment in intermediate coronary stenosis for guiding referral to invasive coronary angiography (ICA). In this study, we...
8.
Moller J, Engstrom T, Jensen L, Eiskjaer H, Mangner N, Polzin A, et al.
N Engl J Med
. 2024 Apr;
390(15):1382-1393.
PMID: 38587239
Background: The effects of temporary mechanical circulatory support with a microaxial flow pump on mortality among patients with ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock remains unclear. Methods:...
9.
Hansen K, Maehara A, Noori M, Troan J, Fallesen C, Hougaard M, et al.
Contemp Clin Trials Commun
. 2024 Feb;
38:101260.
PMID: 38384894
Introduction: Percutaneous coronary intervention with implantation of a bioresorbable scaffold (BRS) provide the vessel support for a limited period allowing the vessel to restore normal vasomotion after degradation of the...
10.
Noori M, Christiansen E, Raungaard B, Junker A, Christensen M, Kahlert J, et al.
Catheter Cardiovasc Interv
. 2023 Dec;
103(2):276-285.
PMID: 38091338
Background: Patients with acute coronary syndromes (ACS) may have worse outcomes after percutaneous coronary intervention compared to patients without ACS. Aims: To compare 5-year efficacy and safety outcomes in patients...